CEACAM5 and breast cancer: Wu SG et al. reported that CEA serum levels were higher in patients with HER2 positive BC and lower in those with triple-negative BC as undifferentiated subtype which justifies that different molecular subtypes have different biological behaviors (Wu et al., 2014).